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The present invention relates to the synthesis of intermediates 
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(2), (4) Date: Feb. 15, 2012 thereof. 
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SYNTHESIS OF TTX INTERMEDIATES 
FIELD OF THE INVENTION 
[0001] The present invention relates to the synthesis of 
TTX intermediates and their analogs. 
BACKGROUND OF THE INVENTION 
[0002] Tetrodotoxin (TTX), octahydro-12-(hydroxym 
ethyl)-2-imino-5,9:7,10a-dimethano-10aH-[1,3]dioxocino 
[6,5-d]pyrimidine-4,7,10,11,12-pentol is a powerful neuro 
toxin Which selectively binds to the sodium channel proteins 
inhibiting their cell membrane function. Tetrodotoxin Was 
isolated for the ?rst time in 1909 from the ovaries of puffer 
?sh and Was named after the puffer ?sh “tetraodontidae” 
family. Despite being a small molecule, it has an extremely 
complex structure characterized by a dioxaadamantane skel 
eton, a guanidine residue Which is part of a hemiaminal and an 
orthoacid bridge. 
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[0003] It must also be highlighted that TTX is normally 
present as a mixture of tWo possible tautomers: an orthoester 
and a hydroxylactone (Scheme 1). The ratio of both tautomers 
depends on the medium in Which the TTX is present. 
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[0004] Due to its novel structure and high density of func 
tional groups, only after extensive efforts did Hirata-Goto et 
al. (Goto, T.; Kishi,Y.; Takahashi, S.; Hirata,Y., Tetrahedron 
1965, 21, 2059-2088), Tsuda et al. (Tsuda, K.; Ikuma, S.; 
KaWamura, M.; TachikaWa, K.; Sakai, K.; Tamura, C.; 
Amakasu, 0., Chem. Pharm. Bull, 1964, 12, 1357-1374) and 
WoodWard et al. (Woodward, R. B., Pure Appl. Chem. 1964, 
9, 49-74; WoodWard, R. B.; Gougoutas, I. Z., J. Am. Chem. 
Soc. 1964, 86, 5030) independently arrived at the same struc 
ture in 1964. Finally, in 1970 absolute stereochemistry Was 
determined unambiguously by X-ray crystallographic analy 
sis of its derivative (Furusaki, A.; Tomie, Y.; Nitta, I. Bull. 
Chem. Soc. Jpn. 1970, 43, 3325-3331). 
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[0005] Tetrodotoxin blocks sodium diffusion through the 
sodium channel, preventing depolariZation and propagation 
of action potentials in nerve cells. The TTX-Na channel bind 
ing site is extremely tight (KdIlO'1O nM). Therefore it is an 
essential tool in pharmacological studies related to sodium 
channel proteins. 
[0006] Furthermore, tetrodotoxin, due to its analgesic 
properties, is a promising neW drug candidate in the ?eld of 
pain management. 
[0007] Extraction and puri?cation of natural TTX is com 
plicated and depends on the availability of the suitable animal 
source. There is therefore an existing need of providing larger 
amounts of tetrodotoxin and its analogues, and researchers 
seek neW inexpensive and e?icient synthesis. Up until noW, 
only a handful of total syntheses have been described (Kishi, 
Y.; Nakatsubo, F.;Aratani, M.; Goto, T.; Inoue, S.; Kakoi, H.; 
Tetrahedron Len. 1970, 59, 5127-5128; Kishi,Y.; Nakatsubo, 
F.; Aratani, M.; Goto, T.; Inoue, S.; Kakoi, H.; Tamino, H.; 
Sugiura, S. J. Am. Chem. Soc. 1972, 94, 9217-9219; Kishi,Y.; 
Nakatsubo, F.; Aratani, M.; Goto, T.; Inoue, S.; Kakoi, H.; 
Tamino, H.; Sugiura, S. J Am. Chem. Soc. 1972, 94, 9219 
9220; Kishi,Y.; Nakatsubo, F.; Aratani, M.; Goto, T.; Inoue, 
S.; Kakoi, H.; Tamino, H.; Sugiura, S. J. Am. Chem. Soc. 
1972, 94, 9220-9221), Isobe et al. in January 2003 (Isobe, M. 
et al, J. Am. Chem. Soc, 2003, 125, 8798-8805). Dubois at al. 
in June 2003 (Du Bois, 1.; Hinman, A. J. Am. Chem. Soc. 
2003, 125, 11510-11511), andIsobe et al., have described an 
additional asymmetric total synthesis comprising 62 steps 
and an overall yield of approximately 1% from a vinilic 
methyl intermediate (Isobe, M.; Urabe, D.; NishikaWa, T. 
Angew. Chem. Int. Ed. 2004, 43, 4782-4785). Further 
improvements by the same author have been published in 
2006 (Isobe, M.; Urabe, D.; NishikaWa, T.; Urabe, D. Chem. 
Asian. J. 2006, 1-2, 125-135). 
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[0008] For the purposes of the present invention “TTX 
analogs” are those described in US. Pat. No. 5,846,975 (in 
cluded herein by reference). From column 3 line 40 to column 
6 line 40 US. Pat. No. 5,846,975 describes a general formula 
of knoWn TTX analogs, for example, anhydroustetrodotoxin, 
tetrodaminotoxin, methoxytetrodotoxin, ethoxytetrodotoxin, 
deoxytetrodotoxin and tetrodonic acid, 6-epi-tetrodotoxin, 
1 l-deoxytetrodotoxin as Well as hemilactal type TTX deriva 
tives (e.g. 4-epi-TTX, 6-epi-TTX, ll-deoxy-TTX, 4-epi-11 
deoxy-TTX, TTX-8-O-hemisuccinate, chiriquitoxin, 1 1 -nor 
TTX-6(S)-ol, 11-nor-TTX-6(R)-ol, 11-nor-TTX-6,6-diol, 
1 l-oxo-TTX and TTX-1 1-carboxylic acid), lactone type 
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TTX derivatives (e.g. 6-epi-TTX (lactone), 11-deoxy-TTX 
(lactone), 11-nor-TTX-6(S)-ol (lactone), 11-nor-TTX-6(R) 
ol (lactone), 11-nor-TTX-6,6-diol (lactone), 5-deoxy-TTX, 
5,11-dideoxy-TTX, 4-epi-5,11-dideoxy-T”IX, 1-hydroxy-5, 
ll-dideoxy-TTX, 5,6,11-trideoxy-TTX and 4-epi-5,6,11 
trideoxy-TTX) and 4,9-anhydrous type TTX analogs (e.g. 
4,9-anhydrous-TTX, 4,9-anhydrous-6-epi-TTX, 4,9-anhy 
drous-1 1 -deoxy-TTX, 4,9-anhydrous-TTX-8-O-hemisucci 
nate, 4,9-anhydrous-TTX-1l-O-hemisuccinate). The typical 
TTX analogs possess only 1/s to 1A0 of the TTX toxicity in 
mice, based upon bioassay in mice. It has been observed that 
these derivatives produce joint action and do not interact 
adversely. 
[0009] Isobe also described the synthesis of different non 
natural tetrodotoxin analogs following similar strategies as 
those described for tetrodotoxin. Speci?cally, Isobe et al. 
described the synthesis of (—)-5,1l-dideoxytetrodotoxin 
(Isobe, M.;Asai, M.; Ohyabu, N.;Yamamoto, N.; NishikaWa, 
T. AngeW. Chem. Int. Ed. 1999, 38, 3081-3084), (—)-8,11 
dideoxytetrodotoxin (Isobe, M.; Asai, M.; IWabuchi, T.; 
Yoshida, K.; Urabe, D.; NishikaWa, T. Org. Len. 2002, 16, 
2679-2682; Isobe, M.; Asai, M.; IWabuchi, T.; Yoshida, K.; 
Urabe, D.; NishikaWa, T. Chem. Eur J. 2004, 10, 452-462) 
and 11-deoxytetrodotoxin (Isobe, M.; Asai, NishikaWa, T. J. 
Am. Chem. Soc. 2002, 124, 7847-7852). 
[0010] Sato et al, described a racemic total synthesis of 
tetrodotoxin from myo-inositol With approximately 0.14% 
overall yield after 40 steps (Sato, K.; Akai, S.; Sugita, N. 
OhsaWa, T.; Kogure, T.; Shoji, H.; Yoshimura, J. J Org. 
Chem. 2005, 70, 7496-7504). 
[0011] Finally, Sato et al., recently described an asymmet 
ric total synthesis of tetrodotoxin from D-glucose With 
approximately 0.13% overall yield after 40 steps (Sato, K.; 
Akai, S.; Sugita, N.; Yoshimura, J. J. Org. Chem. 2008, 73, 
1234-1242). 
[0012] Furthermore, additional discussions relating to dif 
ferent synthetic methods for tetrodotoxin and its analogs can 
also be revieWed in Koert, U. T. Angew. Chem. Int. Ed. 2004, 
43, 5572-55769. 
[0013] International application PCT/EP2008/051653 
describes 1-aZaspiro[3.5]nonan-2-one-5,7-carbolactone and 
5 ,7-protected-1 -aZaspiro [3 .5]nonan-2-one derivatives. 
[0014] Hydroxylated lactams serving as starting material 
for the derivatives of the present invention are prepared in 
international application PCT/EP2005/005149. 
[0015] In vieW of all of the above there is an existing need 
of providing an alternative inexpensive and ef?cient synthesis 
of tetrodotoxin and analogs thereof, Which can be used for the 
industrial production of su?icient amounts of these com 
pounds. Furthermore, neW analogues With useful biological 
and pharmacological properties Will be readily available by 
means of neW synthetic strategies. 
SUMMARY OF THE INVENTION 
[0016] The authors of the invention, on their continuous 
effort to discover an industrially viable synthesis, have dis 
covered that the intermediates of the invention are promising 
intermediate products for synthesizing TTX and analogs 
thereof. Therefore, a ?rst aspect of the invention relates to a 
compound of formula (II), stereoisomers, salts or solvates 
thereof, 
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[0017] The preparation of the compounds of formula (II) 
alloWs e?iciently functioning positions 4a and 5 of TTX 
according to the TTX numbering While at the same time 
introduces carbon 4. Additionally, it opens the door to the 
synthesis of more advanced intermediates in the TTX synthe 
sis, such as the compounds of formula (III), (IV), (V), (VI), 
(VII), (VIII), (IX), 0(a), (XI), @(II), @(III) and @(IV) each of 
Which forms an additional aspect of the invention. 
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[0018] Additional aspects of the invention are methods for 
synthesizing said compounds of formula (II), (III), (IV), (V), 
(VI), (VII), (VIII), (IX), (IX), 0(a), @(I), (XII), @(III) and 
@(IV) as Well as their use as intermediates in the synthesis of 
TTX and analogs thereof. These compounds, as Well as their 
more particular embodiments are called “compounds of the 
invention” throughout the present invention. 
[0019] These intermediates of the invention form advanced 
intermediates in the TTX synthesis. Additionally, the synthe 
sis also alloWs obtaining TTX analogs by means of modifying 
the different positions in a ?exible manner. Methods similar 
to those described in other documents mentioned above (for 
example, in the Sato or Isobe publications) alloW constructing 
the orthoester and the guanidinium ring from the compounds 
of the invention. 
DETAILED DESCRIPTION OF THE INVENTION 
De?nitions 
[0020] Except in the examples, the numbering folloWed to 
designate the positions in the compounds of the invention has 
been the folloWing: 
[0021] In other Words, this is the numbering referred to 
When it is indicated that the number of a speci?c position is 
“according to the TTX numbering”. 
[0022] In the present document the folloWing terms have 
the indicated meanings: 
[0023] “Alkyl” refers to a straight or branched hydrocarbon 
chain radical consisting of carbon and hydrogen atoms, con 
taining no saturation, having 1-12, preferably one to eight, 
more preferably one to six carbon atoms, and Which is bound 
to the rest of the molecule by a single bond, e.g., methyl, 
ethyl, n-propyl, i-propyl, n-butyl, t-butyl, n-pentyl, etc. 
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[0024] “Alkenyl” refers to a straight or branched hydrocar 
bon chain radical consisting of carbon and hydrogen atoms, 
containing at least one unsaturation, having 2-12, preferably 
tWo to eight, preferably tWo to six carbon atoms, and Which is 
bound to the rest of the molecule by a single bond. 
[0025] “Alkylidene” refers to straight or branched hydro 
carbon chain radical consisting of carbon and hydrogen 
atoms, having 1-12, preferably one to eight, more preferably 
one to six carbon atoms, and Which is bound to the rest of the 
molecule by a double bond, e. g., methylene (:CH2) or eth 
ylidene (:CHCH3). 
[0026] “Alkynyl” refers to a straight or branched hydrocar 
bon chain radical consisting of carbon and hydrogen atoms, 
containing at least one carbon-carbon triple bond, conjugated 
or not, having tWo to tWelve, preferably tWo to eight, prefer 
ably tWo to six carbon atoms, and Which is bound to the rest 
of the molecule by a single bond, such as 4CCH, 
iCH2CCH, 4CCCH3, iCH2CCCH3. 
[0027] “Aryl” or “Ar” refers to an aromatic hydrocarbon 
radical such as phenyl, naphthyl or anthracyl. 
[0028] “Arylalkyl” refers to an alkyl group bound to the rest 
of the molecule through an alkyl group such as benZyl and 
phenethyl. 
[0029] “Cycloalkyl” refers to cyclic hydrocarbon chain 
radical consisting of carbon and hydrogen atoms, containing 
no saturation, having 3 to 8 carbon atoms, bound to the rest of 
the molecule by a single bond. 
[0030] “Alkoxyl” refers to a radical of the formula -Oalkyl, 
e.g., methoxy, ethoxy, propoxy, etc. 
[0031] “Aryloxy” refers to a radical of formula -Oaryl. 
[0032] “Heterocyclyl” refers to a stable 3- to 15-membered 
ring consisting of carbon atoms and one to ?ve heteroatoms 
selected from the group consisting of nitrogen, oxygen, and 
sulfur, preferably a 4-to 8-membered ring With one or more 
heteroatoms, more preferably a 5- or 6-membered ring With 
one or more heteroatoms. For the purposes of this invention, 
the heterocycle can be a monocyclic, bicyclic or tricyclic ring 
system, Which can include fused ring systems; and the nitro 
gen, carbon or sulfur atoms in the heterocyclyl radical can be 
optionally oxidiZed; the nitrogen atom can be optionally quat 
emiZed; and the heterocyclyl radical can be partially or com 
pletely saturated or aromatic. Examples of said heterocycles 
include, but are not limited to, aZepines, benZimidaZole, ben 
ZothiaZole, furan, isothiaZole, imidaZole, indole, piperidine, 
piperaZine, purine, quinoline, thiadiaZole, tetrahydrofuran. 
[0033] “Amino” refers to a radical of formula iNHZ, 
iNHR", iNR"R"', Wherein R" and R"' independently rep 
resent a group selected from the group consisting of substi 
tuted or unsubstituted alkyl, substituted or unsubstituted alk 
enyl, substituted or unsubstituted alkynyl, substituted or 
unsubstituted aryl and substituted or unsubstituted arylalkyl. 
[0034] “Hydroxyl protecting group” refers to a group 
blocking the OH function for subsequent reactions and can be 
removed under controlled conditions. Hydroxyl protecting 
groups are Well knoWn in the art, representative protecting 
groups are: 
[0035] silyl ethers of formula iSi(R')3, such as trimethyl 
silyl ether, triethylsilyl ether, tert-butyldimethylsilyl ether, 
tert-butyldiphenylsilyl ether, tri-isopropylsilyl ether, diethyl 
isopropylsilyl ether, thexyldimethylsilyl ether, triphenylsilyl 
ether, di-ter‘t-butylmethylsilyl ether; 
[0036] alkyl and arylalkyl ethers such as methyl ether, tert 
butyl ether, benZyl ether, p-methoxybenZyl ether, 3,4 
dimethoxybenZyl ether, trityl ether; allyl ether; 
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[0037] alkoxymethyl and aryloxy ethers of formula 
4CH24OiR', such as methoxymethyl ether, 2-methoxy 
ethoxymethyl ether, benZyloxymethyl ether, p-methoxyben 
Zyloxymethyl ether, 2-(trimethylsilyl)ethoxymethyl ether; 
tetrahydropyranyl and related ethers; methylthiomethyl 
ether; 
[0038] esters of formula 4C(:O)R' such as acetate ester, 
benZoate ester; pivalate ester, methoxyacetate ester, chloro 
acetate ester, levulinate ester; 
[0039] carbonates of formula 4C(:O)iOiR' such as 
benZyl carbonate, p-nitrobenZyl carbonate, ter‘t-butyl carbon 
ate, 2,2,2-trichloroethyl carbonate, 2-(trimethylsilyl)ethyl 
carbonate, allyl carbonate; and 
[0040] sulphates such as SO3.py. 
[0041] In all the above formula R' represents a group 
selected from the group consisting of substituted or unsubsti 
tuted alkyl, substituted or unsubstituted alkenyl, substituted 
or unsubstituted alkynyl, substituted or unsubstituted aryl and 
substituted or unsubstituted arylalkyl. Additional examples 
of hydroxyl protecting groups can be found in reference 
books such as Greene and Huts “Protective Groups in Organic 
Synthesis”, John Wiley & Sons, Inc., NeW Jersey, 2007. 
[0042] “Amino protecting group” refers to a group block 
ing the NH, function for subsequent reactions and can be 
removed under controlled conditions. Amino protecting 
groups are Well knoWn in the art, representative protecting 
groups are carbamates, e.g. carbamates of formula iC(:O) 
OR'; amides, e.g. amides of formula 4C(:O)R', such as 
substituted or unsubstituted acetates; or silyl moieties of for 
mula iSi(R')3; Wherein R' is as de?ned above. Different 
alkyl moieties can also serve as amino protecting groups. Said 
alkyl groups can optionally be substituted With one or more 
substituents such as halogen, hydroxyl, alkoxyl, alkyloxym 
ethyl ethers, carboxy, cyano, carbonyl, acyl, alkoxycarbonyl, 
amino, nitro, mercapto and alkylthio. Additional examples of 
amino protecting groups can be found in reference books 
such as Greene and Ruts “Protective Groups in Organic Syn 
thesis”, John Wiley & Sons, Inc., NeW Jersey, 2007. 
[0043] References herein to substituted groups in the com 
pounds of the present invention refer to the speci?ed moiety 
that may be substituted at one or more available positions 
With one or more suitable groups, e.g., halogen such as ?uo 
rine, chlorine, bromine and iodine; cyano; hydroxyl; nitro; 
aZido; alkanoyl such as a Cl_6 alkanoyl such as acyl and the 
like; carboxamido; alkyl groups including those groups hav 
ing 1 to 12 carbon atoms or 1 to 6 carbon atoms and more 
preferably 1-3 carbon atoms; alkenyl and alkynyl groups 
including groups having one or more unsaturated bonds and 2 
to 12 carbons or 2 to 6 carbon atoms; alkoxyl groups having 
one or more oxygen bonds and 1 to 12 carbon atoms or 1 to 
approximately 6 carbon atoms; alkoxyl such as phenoxy; 
alkylthio groups including those moieties having one or more 
thioether bonds and 1 to about 12 carbon atoms or 1 to 6 
carbon atoms; alkylsul?nyl groups including those moieties 
having one or more sul?nyl bonds and 1 to 12 carbon atoms or 
1 to 6 carbon atoms; alkylsulfonyl groups including those 
moieties having one or more sulfonyl bonds and 1 to 12 
carbon atoms or 1 to 6 carbon atoms; aminoalkyl groups such 
as those groups having one or more N atoms and 1 to 12 
carbon atoms or 1 to 6 carbon atoms; carbocylic aryl having 
6 or more carbons, particularly phenyl or naphthyl and ary 
lalkyl such as benZyl. Unless otherWise indicated, an option 
ally substituted group can have a substituent at each substi 
tutable position of the group, and each substitution is 
independent of the other. 
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[0044] Unless otherwise stated, it is understood that the 
compounds of the invention also include compounds Which 
differ only in the presence of one or more isotopically 
enriched atoms. For example, compounds of formula (II), 
(III), (Iv), (V), (VI), (VII), (VIII), (IX), ma), (XI), (X11), 
(XIII) or @(IV) Wherein a hydrogen has been substituted With 
a deuterium or tritium, and/or the substitution of a carbon 
With 13 C- or l4C-enriched carbon, and/or 15 N-enriched nitro 
gen and/or the substitution of an oxygen with 18O, are Within 
the scope of this invention. 
Compounds of the Invention 
[0045] As indicated above, aspects of the present invention 
are the compounds of formula (II), (III), (IV), (V), (VI), (VII), 
(VIII), (IX), (Xa), @(I), (XII), @(III) or (XIV), stereoisomers, 
salts or solvates thereof, 
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[0046] wherein 
[0047] R1 is selected from hydrogen, cyano, substituted or 
unsubstituted alkyl, substituted or unsubstituted alkenyl, sub 
stituted or unsubstituted alkynyl and NReRf, Wherein Re and 
Rf are each independently selected from H, OH, OPr, substi 
tuted or unsubstituted alkyl, substituted or unsubstituted 
cycloalkyl, substituted or unsubstituted alkenyl, substituted 
or unsubstituted aryl, substituted or unsubstituted heterocy 
clyl, substituted or unsubstituted alkoxyl, substituted or 
unsubstituted aryloxyl, substituted or unsubstituted amino 
and halogen; 
[0048] R2 is selected from hydrogen, OH, or OPr; or 
[0049] R1 and R2 together form a group selected from :O, 
alkylidene and iCH2iOiPriOi; 
[0050] E is selected from the group consisting of ?uorine, 
chlorine, bromine, iodine, iSeRB, 4OiNR13, iSRM, 
PO(O-alkyl)2 and PO(O-aryl)2, Wherein 
[0051] R1 3 is selected from the group consisting of aryl and 
alkyl; 
[0052] R14 is selected from the group consisting of aryl, 
[0053] R9 and R10 are each independently selected from 
hydrogen, OH, OPr and :O; or together form a 4OiPri 
Oi group; 
[0054] W is selected from the group consisting of iH, 
substituted or unsubstituted alkyl, substituted or unsubsti 
tuted aryl, substituted or unsubstituted arylalkyl, substituted 
or unsubstituted heterocyclyl and substituted or unsubstituted 
alkenyl; 
[0055] Ra and Rb are each independently selected from H, 
OH, OPr, Se-aryl, substituted or unsubstituted alkyl, substi 
tuted or unsubstituted cycloalkyl, substituted or unsubstituted 
alkenyl, substituted or unsubstituted aryl, substituted or 
unsubstituted heterocyclyl, substituted or unsubstituted 
alkoxyl, substituted or unsubstituted aryloxyl, substituted or 
unsubstituted amino and halogen; 
[0056] Pr is a hydroxyl protecting group; 
[0057] Z is iCOOH or 4CHR4R5, Wherein R4 is hydro 
gen, and R5 is OH or OPr; or R4 and R5 together form :0; 
[0058] X is %H(:O) or %N; 
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[0059] Y is selected from the group consisting of ‘0R6, 
iSR6, Se-aryl, iN(R6)2, -+N(R6)3 and iNHR7, 
[0060] Wherein R6 is selected from the group consisting of 
substituted or unsubstituted alkyl, substituted or unsubsti 
tuted cycloalkyl, substituted or unsubstituted alkenyl, substi 
tuted or unsubstituted aryl, substituted or unsubstituted ary 
lalkyl and substituted or unsubstituted heterocyclyl; 
[0061] R7 is selected from the group consisting of substi 
tuted or unsubstituted alkyl, substituted or unsubstituted 
cycloalkyl, substituted or unsubstituted alkenyl, substituted 
or unsubstituted aryl, substituted or unsubstituted arylalkyl, 
substituted or unsubstituted heterocyclyl, 4O-alkyl, iO 
aryl, 4O-arylalkyl, Oi(C:O)-alkyl, Oi(C:O)-aryl and 
Oi(C:O)-arylalkyl; 
[0062] X1 is selected from the group consisting of iCN, 
%OORI6, iCON(Rl6)2, CHO, iCHzOH, CH2N(Rl6) 
2iSe-Aryl, iSe(:O)-aryl, said aryl being able to be 
optionally substituted, iSiRm, iS(:O)R16, ‘CH 
(ORl6)2, iCH(NHRl6)CN and iCH(ORl6)CN 
[0063] Wherein R16 is in each case independently selected 
from the group consisting of hydrogen, alkyl and aryl; tWo 
R16 groups being able to form a linear or branched alkylidene 
group, optionally substituted With one or more carbonyl 
groups; and 
[0064] R15 is independently in each case ‘OH or 4OPr. 
[0065] The compounds of the invention are intermediate 
products especially interesting for synthesizing TTX, provid 
ing a ?exible pathWay to its different analogs. 
[0066] The invention also provides salts of the compounds 
of the invention With biologically and pharmacologically 
acceptable inorganic and organic acids, non-limiting 
examples of Which are sulfates; halohydrate salts; phos 
phates; loWer alkane sulfonates; arylsulfonates; salts of 
Cl-C2O aliphatic mono-, di- or tribasic acids Which can con 
tain one or more double bonds, an aryl nucleus or other 
functional groups such as hydroxyl, amino, or keto; salts of 
aromatic acids in Which the aromatic nuclei may or may not 
be substituted With groups such as hydroxyl, loWer alkoxyl, 
amino, mono- or di-(loWer alkyl)-amino-sulfonamido. There 
are also included Within the scope of the invention quaternary 
salts of the tertiary nitrogen atom With loWer alkyl halides or 
sulfates, and oxygenated derivatives of the tertiary nitrogen 
atom, such as N-oxides. The persons skilled in the art Will 
select the pharmaceutically acceptable salts When preparing 
dosage formulations. 
[0067] The term “solvate” according to this invention must 
be understood as meaning any form of active compound 
according to the invention Which has another molecule (most 
likely a polar solvent) bound to it through a non-covalent 
bond. Examples of solvates include hydrates and alcoholates, 
e.g. methanolate. 
[0068] The present invention also comprises the different 
stereoisomers of the compounds of the invention. A “stereoi 
somer” in the present patent application refers to compounds 
formed by the same atoms bound by the same bonding 
sequence but Which have different three-dimensional struc 
tures that are not exchangeable. 
[0069] Particular embodiments of the compounds of the 
invention are made up of the compounds of formula (Ila), 
(lllb), (lllc), stereoisomers, salts or solvates thereof 
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(IIa) 
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E R9 
NC R10 
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R10 
Ra N—O 
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I W 
O 
[0070] wherein E, R9, R10, Ra, Rb and W are as have been 
de?ned above. 
[0071] According to a particular embodiment W is aryla 
lkyl, preferably W is CRcRd-aryl, Wherein Rc and Rd are 
each independently selected from H, OH, OPr, substituted or 
unsubstituted alkyl, substituted or unsubstituted cycloalkyl, 
substituted or unsubstituted alkenyl, substituted or unsubsti 
tuted aryl, substituted or unsubstituted heterocyclyl, substi 
tuted or unsubstituted alkoxyl, substituted or unsubstituted 
aryloxyl, substituted or unsubstituted amino and halogen. In 
a particular embodiment Rc is other than hydrogen and Rd is 
hydrogen. According to an additional embodiment Rc and Rd 
are both hydrogen. 
[0072] According to a particular embodiment Ra is hydro 
gen and Rh is selected from the group consisting of halogen, 
preferably bromine, OH, OPr and Se-aryl. In another embodi 
ment Ra and Rh are both hydrogen. 
[0073] According to a particular embodiment, Y is selected 
from OH, alkoxyl, ammonium and iNE(Oi(C:O)-aryl). 
[0074] According to a particular embodiment, E is bromine 
or iodine, preferably bromine. 
[0075] According to a particular embodiment, R9 and R10 
together form a group of formula iOiSi(Rl lR12)iOiSi 
(Rl lRl2)iOi, wherein R1 1 and R12 are independently 
selected from the group consisting of hydrogen, substituted or 
unsubstituted alkyl, substituted or unsubstituted cycloalkyl, 
substituted or unsubstituted alkenyl, substituted or unsubsti 
tuted alkynyl, substituted or unsubstituted aryl and substi 
tuted or unsubstituted heterocyclyl. According to a particular 
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embodiment, R11 and R12 are isopropyl, for example in the 
compounds of formula (II), (III), (IV), (V), (VI), (VII), (VIII), 
(IX), (X), 0(a), Oil), (XII), @(III) or @(IV). 
[0076] According to a particular embodiment, R1 is alkyl 
OPr. According to another particular embodiment, R 1 and R2 
together form :0, alkylidene or iCH4OiPr4Oi. 
According to a particular embodiment, R1 and R2, in the 
compounds of formula Qi), (Xa), (XI), (XII), @(III) or (XIV), 
for example, together form 4CH24OiPr4Oi, Wherein 
Pr is i[(R1l)C(Rl2)]i, Wherein R11 and R12 are as have 
been de?ned above, preferably methyl. In another particular 
embodiment R1 is hydrogen and R2 is OH or OPr. 
[0077] In a particular embodiment, X is CN. 
Synthesis of the Compounds of the Invention 
[0078] An aspect of the present invention is a method for 
synthesiZing a compound of formula (II), stereoisomers, salts 
or solvates thereof, comprising a sequence A Which com 
prises (ai) reacting a compound of formula (I) in the presence 
of a cyanide ion source, and (aii) reacting the intermediate 
obtained in the presence of an electrophile, or a sequence B 
Which comprises (bi) reacting a compound of formula (I) in 
the presence of electrophile, and (bii) reacting the intermedi 
ate obtained in the presence of a cyanide ion source 
(I) 
O 
R9 
R10 
Ra N—O 
\ 
Rb W 
O 
[0079] Wherein R9, R10, Ra, Rb and W are as have been 
de?ned above. 
[0080] The methods for obtaining the compounds of for 
mula (I), starting materials of the present invention, are 
described in patent applications PCT/EP2005/005l49 and 
PCT/EF2005/ 005146, of the same inventors. 
[0081] In Sequence A, step (ai) provides a Michael addition 
on position 4a of the cyclohexenone ring of the compound of 
formula (I). The intermediate enolate of formula (Ia) is pro 
duced as a result of said attack. 
(13) 
9 
O 
R9 
R10 
NC 
Ra N — O 
\ 
Rb W 
O 
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[0082] The electrophile can be added directly in the reac 
tion medium after the reaction With cyanide ion source, With 
out the need of isolating said intermediate enolate of formula 
(Ia). Alternatively, said enolate can be trapped and isolated 
before its reaction With the electrophile. 
[0083] In sequence B, the electrophile is ?rst added to 
provide the corresponding derivative of position 5 (lb) 
(1b) 
0 
E R9 
R10 
Ra N— O 
\ 
Rb W 
O 
[0084] Michael addition on said derivative is then per 
formed With the cyanide ion. According to a particular 
embodiment, the derivative of formula (lb) is isolated and 
then subjected to reaction (bii) in the presence of a cyanide 
ion source. According to a particular embodiment, the reac 
tion (bi) is also performed in the presence of a base, for 
example, an organic base such as a trialkylamine (e.g. triethy 
lamine). 
[0085] Alternatively, the compounds of formula (I) can be 
reacted in the presence of a cyanide ion source and, instead of 
reacting the intermediate obtained in the presence of an elec 
trophile, the intermediate enolate can be reacted With a proton 
source. Compounds of formula (X), stereoisomers, salts or 
solvates thereof are obtained as a result. 
(X) 
R2 R1 
R9 
NC R10 
Ra N—O 
\ 
Rb W 
O 
[0086] Wherein R1, R2, R9, R10, Ra, Rb and W are as 
de?ned above. 
[0087] The different de?nitions for R 1 and R2 radicals in the 
compounds of formula Q() can be obtained by folloWing the 
methods described in the section “Other Reactions” beloW. 
[0088] Of these compounds, the compounds of formula 
(Xa) described above are a novel subgroup especially useful 
for synthesiZing the TTX. As can be seen, these compounds of 
formula 0(a) alloW arriving, in a feW steps, to the compounds 
of formula (XI), @(II), @(III) or @(IV), all of them are also 
novel advanced intermediates for synthesiZing TTX com 
pounds. 
[0089] In another embodiment, the compounds of formula 
(X) can be obtained by means of sequenceA giving rise to the 
compounds of formula (II), folloWed by treatment With base 
(for example, a trialkylamine such as triethylamine) giving 
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rise to the removal of group E. For example, it is possible to 
treat a compound of formula (Ia) With NBS to produce the 
resulting compound of formula (II) Wherein E is bromine, 
Which compound can be converted into a compound of for 
mula (X) by means of treatment With triethylamine. 
O 
R9 
R10 
Ra N— O 
\ 
Rb W 
O 
(I) 
9 
0 R2 R1 
R E R9 
Electrophile 
R10 4P NC R10 
NC 
Ra N — O Ra N — O 
\ \ 
Rb W Rb W 
O O 
(Ia) (II) 
Base 
Base 
—> 
9 
2 
[0090] According to a particular embodiment, Pr in a com 
pound of formula @(e) is 4OiSi(Rl lR12)4OiSi 
(R11Rl2)4Oi, Wherein R11 and R12 are as have been 
de?ned above, Wherein R l l and R1 2 are preferably isopropyl. 
In a compound of formula 0(a) at least one of Ra and Rb is 
preferably hydrogen. 
[0091] The cyanide ion source necessary can be obtained 
from different sources knoWn by the person skilled in the art. 
For example, said sources can be selected from the folloWing 
reactive systems: Ph3P/diethyl aZodicarboxylate (DEAD)/al 
cohol/acetone cyanohydrin (Synlh. C0m. 1995, 25, 1545 
1550; Synzh. Com. 1993, 23, 2481-2484). 
[0092] Other cyanide anion sources are based on reactive 
systems comprising NaCN. The conditions already described 
in the art comprise a mixture of NaCN With one of the fol 
loWing reaction systems: DMSO or nBu4NCN/DMF/heat (J. 
Med. Chem. 1991, 56, 3009-3016; J. Med. Chem. 1966, 31, 
2933-2941), DMSO/heat (J. Med. Chem. 2001, 44, 94-104; 
Tetrahedron Asymmetry, 1996, 7, 1967-1972), Bu4NCN/ 
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DMSO/heat (Bioorg. Med. Chem. Lett. 1999, 9, 841-846), 
DMF/heat (Tetrahedron Letters, 1998, 39, 3357-3358; J. 
Med. Chem. 1994, 37, 4195-4210), [(CH3)2N]3PO (J Chem. 
Soc. Chem. Com. 1982, 7, 404-406) or conditions in which 
sodium bicarbonate is present, such as NaCN/NaHCO3/H2O/ 
Et2O/r.t., NaCN/NaHCO3/Et2O/rt. or NaCN/NaHCO3/ 
THF/-H2O (J Med. Chem. 1992, 35, 2721-2727; Carbohy 
drate Research 1991, 216, 399-411; J. Med. Chem. 1998, 41, 
4636-4647; Carbohydrate Research 1991, 216, 399-411). 
Also, NaCN in the presence of 1 -methyl-1H-pyrrole provides 
the desired cyanide anion. 
[0093] In another embodiment, the reaction can be per 
formed in the presence of KCN (J. Am. Chem. Soc. 1958, 80, 
4677-4680). The conditions already described in the art com 
prise a mixture of KCN with one of the following reaction 
systems: Et2O/H2O (Tetrahedron Letters, 2001, 42, 6259 
6262), THF/rt. (CarbohydrateResearch 1994, 254, 133-140) 
or CH2Cl2/H2O/r.t., with or without NaHCO3 (J Chem. Soc. 
Perkin Trans 1. 1985, 1067-1072). 
[0094] In another embodiment, the reaction can be per 
formed in the presence of LiCN. The conditions already 
described in the art comprise a mixture of LiCN with one of 
the following reaction systems: Me3 SiCl/THF/rt. (Synthesis, 
1986, 12, 1054-1055), DMF/[(CH3)2N]3PO (Bioorg. Med. 
Chem. Lett. 1996, 6, 1897-1900), diethyl cyanophosphonate/ 
THF/r.t. (Chem. Pharm. Bull. 1986, 34, 4620-4628; Tetrahe 
dron Letters, 1989, 30, 3681-3684) or DMF (Bioorg. Med. 
Chem. Lett. 2000, 10, 2417-2419). 
[0095] Copper cyanide is also a useful cyanide anion source 
(CuCN/HNaCO3)/H2O/EtO2; Tetrahedron. 1988, 44, 4895 
4904). 
[0096] In another embodiment, the reaction can be per 
formed in the presence of HCN. The conditions already 
described in the art comprise a mixture of HCN with one of 
the following reaction systems: Pyridine/rt. (J. Chem. Soc. 
Perkin Trans 1. 1994, 1067-1072), Et3N/CH2Cl2/0o C. (Car 
bohydrate Research 1986, 155, 236-246) or the in situ gen 
eration of HCN mixing Zn(CN)2 and AlCl3 (Tetrahedron 
Asymmetry, 1990, 1, 187-198). 
[0097] Therefore, according to an embodiment, the reagent 
providing a cyanide anion has a formula MCN, wherein M is 
lithium, potassium, sodium or copper. 
[0098] Trialkylsilyl cyanides are also very widespread cya 
nide anion sources (J Org. Chem. 2003, 3094-3103; J. Am. 
Chem. Soc. 1973, 5822-5823; J. Chem. Soc. Perkin Trans 1. 
1988, 2305-2307). The conditions already described in the art 
comprise a mixture of trialkylsilyl cyanide with one of the 
following reaction systems: TMSCN/DABCO or TMSCN/ 
(DHQ)2AQN (J Am. Chem. Soc. 2003, 125, 9900-9901), 
TMSCN/BF3/CH2Cl2/rt. or TMSCN/B133.Et2O/CH2Cl2/rt. 
(Tetrahedron Letters, 1990, 31, 71-74; Tetrahedron Letters, 
1990, 31, 71-74; Tetrahedron Letters, 1990, 31, 71-74; Car 
bohydrate Research 1994, 258, 77-86), TMSCN/ crown ether/ 
KCN(cat)/toluene/—30o C. (J Am. Chem. Soc. 1985, 107, 
4577-4579; Tetrahedron Letters, 1994, 35, 7901-7904), 
TMSCN/amine/CH2Cl2/0o C. (Chemistry Letters, 1991, 125, 
537-540), TMSCN/I2/20-30o C. (Tetrahedron 2000, 35, 
6533-6540), TMSCN/ZnIZ/heat (Tetrahedron Asimmetry. 
1994, 9, 805-816), TMSCN/CaO/Toluene/—40o C. (J. Chem. 
Soc. Chem. Com. 1991, 15, 1035-1036), TMSCN/Ph3P(cat)/ 
CH2Cl2 (Tetrahedron Letters, 1986, 27, 2757-2760), 
TMSCN/Lewis acid (Tetrahedron Letters, 1983, 39, 967 
974), TMSCN/catalyst (Tetrahedron 2001, 57, 771-779); 
TMSCN/ZnI2(cat) (Tetrahedron 1994, 50, 2821-2830), 
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TBDMSCN/ZnI2/CH2CI2 (J. Org. Chem. 1993, 58, 159-164; 
Bull. Chem. Soc. Jpn. 2001, 74, 997-1008), (alkyl)3SiCN/ 
DiCl(cat)/without solvent (J. Org. Chem. 2005, 70, 6530 
6532). 
[0099] According to an additional embodiment, the 
reagents providing a cyanide anion are a dialkylaluminium 
cyanide of formula (alkyl)2-Al4CN or a trialkylsilyl cyanide 
of formula (alkyl)3Si4CN, which are available on the mar 
ket. 
[0100] According to a preferred embodiment, the reaction 
proceeds in the presence of TMSCN or Et2AlCN. 
[0101] According to a particular embodiment, electro 
philes useful for the preparation of the compounds of formula 
(II) are selected of the group consisting of RBSiSRB, for 
example, Me-SiS-Me (Yadav, V. K.; Babu, K. G.; ParweZ, 
M.J. Org. Chem. 2004, 69, 3866-3874), or Ph-SiS-Ph (Mo 
rel, G.; Marchand, E.; Foucaud, A. Synthesis 1980, 11, 918 
921); Rl3iSiSO2iRl3, for example, Ph-SiSO2-Ph 
(Lythgoe, B.; Waterhouse, I.; J Chem. Soc. P T 1 1979, 
2429-2436); CliSiPO(O-alkyl)2, for example, CliSi 
PO(OEt)2 (Dybowski, P.; Skowronska, A. Tetrahedron Lett. 
1991, 32, 4385-4388); CliSiC(:O)O-alkyl, for example, 
MeO4COiSiCl (Sanemitsu, Y.; Kawamura, S.; Tanade, 
Y. J Org. Chem. 1992, 57, 1053-1056); CliPO(O-alkyl)2, 
for example, CliPO(OEt)2 (Kandil, A. A.; Porter, T. M.; 
Slessor, K. N. Synthesis 1987, 4, 411-413); ONR13, for 
example, PhiNO (Momiyama, N.;Yamamoto, H.; Org. Lett. 
2002, 21, 3579-3582); BrSeRB, for example, BrSePh (Roll 
inson, S. W.; Amos, R. A.; KatZenellenbogen, J. A. J. Am. 
Chem. Soc. 1981, 103, 4114-4125), or BrSeMe (Aoki, I.; 
Nishibayashi, U.; Sakae, U. Bull. Chem. Soc. Japan 1995, 68, 
337-340); RBSeiSeRB, for example, Ph-SeiSe-Ph 
(Wovkulich, P. M.; Baggiolim, E. G.; Hennessy, B. M.; 
Uskokovic, M. R. Heterocycles 1993, 35, 791-806). Those 
mentioned between parenthesis indicate a reference in which 
possible reaction conditions for using the reagents are 
described. Other conditions can be found in reference books 
such as “Advanced Organic Chemistry: reactions, mecha 
nisms and structures”, March, 1., fourth edition, Wiley-inter 
science. 
[0102] Thus, the different intermediate compounds of the 
invention and the starting materials can be prepared using a 
basic set of simple reactions which allow speci?cally protect 
ing and functionaliZing the different positions. These meth 
ods will be explained below. Throughout the description and 
claims the con?gurations given are solely relative con?gura 
tions. 
[0103] The enantiomerically pure derivatives of the com 
pounds of the invention can be prepared using starting mate 
rials or reagents (for example, Sharpless dihydroxylation or 
epoxidation of a double bond) having the opposite optical 
rotation. Furthermore, the conventional techniques for sepa 
rating diastereoisomers and enantiomers are generally known 
by the persons skilled in the art. 
[0104] As has been mentioned above, the starting materials 
of the present invention can be obtained by methods 
described in documents PCT/EP2005/005149 and/or PCT/ 
EP2005/005146. The key intermediate products described in 
document PCT/EP2005/005146 are benZodienones with the 
following formula 
US 2012/0142911A1 
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[0105] wherein the substitution in position Z can create a 
stereogenic centre. In document PCT/EP2005/005146 a pre 
ferred embodiment is that Wherein Z is iCRaRbi, Wherein 
Ra and Rb are different and thus create a chiral centre. Thus, 
according to a preferred embodiment Ra and Rb in the com 
pounds of the invention are different, and a chiral centre is 
thus created. 
[0106] Furthermore, document PCT/EP2005/005146 
describes as a preferred embodiment compounds Wherein the 
substituent W of the benZodienones above is an arylalkyl 
group, more preferably Wherein W is 4CRaRb-Q, Wherein 
Ra and Rb in the connector essentially have the same meaning 
as in the present application, and the substituent Q has at (pi) 
interactions With those moieties of benZodienone. Thus, 
10 
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[0107] Therefore, by using the chiral materials described in 
documents PCT/EP2005/005149 and/ or PCT/EP2005/ 
005146, the speci?c stereoisomers and enantiomers of the 
compounds described in the present invention can be 
obtained. 
[0108] To obtain the different compounds of formula (II) or 
of formula (X) or of formula Gil), the latter or the precursors 
thereof can be subjected to one or more steps Which are 
selected from the group consisting of: 
[01 09] a) reducing the ketone to hydroxyl group, optionally 
folloWed by protecting and/or inverting the con?guration of 
said hydroxyl group; 
[0110] b) ole?nating the ketone to obtain an alkylidene 
group, optionally folloWed by dihydroxylation; 
[0111] c) ole?nating the ketone to obtain an alkylidene 
group, optionally folloWed by dihydroxylation and subse 
quent protection of at least one of the hydroxyl groups 
formed; 
[0112] d) protecting the ketone; 
[0113] e) alkylating the ketone; and 
[0114] f) aminating the ketone. 
[0115] The ketone of a compound of formula (Ila) for 
example can be reduced to hydroxyl and to subsequently 
protect it, or it can be subjected to a Wittig reaction to obtain 
methylene derivative. The ketone can also be protected (see 
scheme 2) 
Scheme 2 
CH2 
E R9 
NC R10 
Ra N—O 
\ 
Rb W 
o 
O O 
N_ 
b 
0 
another chiral source arises When Ra and Rb in said connector 
are different, preferably Wherein W is 4CHRa-Q (e.g., (—) 
(S)-1-(1-phenylethoxy)-1-aZaspiro[3.5]nona-5,8-diene-2,7 
dione, Which is described as compound 5d in document PCT/ 
EP2005/005146). As described in document PCT/EP2005/ 
005146 said con?gurations provide a stereogenic centre 
alloWing the selectivity or speci?city of any other reaction, 
distinguishing the tWo double bonds of the benZodienones 
mentioned, Which are intermediate products in the synthesis 
of the compounds of the invention. This Will open up a path 
Way to diastereoselective and enantioselective synthesis. 
0 OH 
E R9 E R9 E R9 E 
NC R10 <— NC R10 —> NC R10 —> NC 
R3. 0 R3. N — 0 R3. N — 0 R3. 
\ \ \ 
R W Rb W Rb W Rb 
O O 
OPr 
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N— O 
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[0116] Another aspect of the present invention is a method 
for synthesiZing a compound of formula (III) or Gil), stere 
oisomers, salts or solvates thereof, Which comprises reacting 
a compound of formula (II) or Q(), respectively, in the pres 
ence of a hydride. The spirolactam ring is opened by means of 
this reaction, carbon 10 being able to obtain (according to the 
TTX numbering) either aldehyde or alcohol depending on the 
nature of the hydride and of the reaction conditions (for 
example, by means of choosing the solvent or the number of 
hydride equivalents). Optionally, the resulting hydroxyl can 
be protected. Another alternative is oxidizing the aldehyde or 
alcohol obtained to obtain the corresponding carboxylic acid. 
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[0117] The spirolactam ring is opened in the presence of a 
hydride, preferably in the presence of an aluminium or boron 
hydride derivative, for example, 9-BBN, NaBH, DIBALH or 
LiAlH4 (see for example chapter 19 of “Advanced Organic 
Chemistry; reactions, mechanisms and structures”, March, 
1., 5th edition, Wiley-interscience). Other non-limiting 
hydrides and methods suitable for the present invention are 
described in Handbook of Reagents for Organic Synthesis. 
Oxidizing and Reducing Agents. Eds; John Wiley & Sons: 
Baf?ns Lane, Chichester, 1999: diborane (pages 126-132), 
BH3.SMe2 (pages 48-51), BH3.THF (pages 52-57), ((CH3) 
24CH(CH3))2BH (pages 160-163) or diisopinocamphe 
nylborane (pages 146-149). 
[0118] An additional aspect of the invention is a method for 
synthesiZing a compound of formula (IV), stereoisomers, 
salts or solvates thereof, Which comprises 
[0119] (a) reacting a compound of formula (IIIa) in the 
presence of a base. 
[0120] or, 
[0121] (b) When the compound of formula (IV) Wherein Ra 
is iSe-aryl is to be obtained, reacting a compound of for 
mula (IIIb) in the presence of halogen-Se-aryl or aryl-Sei 
Se-aryl, and a base, preferably a cyclic amine, preferably 
morpholine. 
[0122] Methods (a) and (b) for obtaining compounds of 
formula (IV) can also be used to obtain the compounds of 
formula (V), depending on the base used. This also forms 
additional aspects of present invention. In some cases the 
compounds of formula (V) or the compounds of formula (IV) 
are exclusively obtained, and in other occasions mixtures of 
both (see examples 7 and 8 beloW). 
[0123] The compounds of formula (V), for example, for 
mally result from the removal of HBr from a compound of 
formula (IV). Therefore, harsher conditions (higher tempera 
ture, stronger bases, excess of bases, greater reaction times, 
etc.) Would favor the formation of compounds of formula (V). 
As seen by comparing Examples 7 and 8, a more prolonged 
exposure to the base (example 8) and/or the excess thereof 
favors the removal and therefore the formation of the com 
pounds of formula (V). In addition, Weaker bases cannot 
perform the removal and they favor the formation of com 
pounds of formula (IV). Other conditions Which can favor the 
formation of compounds of formula (IV) are the use of less 
base and shorter reaction times. 
[0124] According to a particular embodiment, the base 
selected from the group consisting of phosphaZenes (P1, P2, 
P3 and P4) and related bases such as Verkade’s base; DBU; 
DABCO; cyclic aliphatic amines such as pyridine, 4-dim 
ethylaminopyridinpiperidin or morpholine; trialkylamines 
such as triethylamine or the diisopropylamine. According to a 
particular embodiment, said amines are supported on poly 
mer supports. According to a particular embodiment the base 
is DBU. 
[0125] In a particular embodiment, the compound of for 
mula (V) or of formula (IV) obtained is reacted in an acid 
medium in the presence of a reagent Which is selected from 
the group consisting of HOR6, HSR6, Se-aryl, aryl-SeiSe 
aryl, HN(R6)2, N(R6)3 and iNHR7, 
[0126] Wherein 
[0127] R6 is selected from the group consisting of substi 
tuted or unsubstituted alkyl, substituted or unsubstituted 
cycloalkyl, substituted or unsubstituted alkenyl, substituted 
or unsubstituted aryl, substituted or unsubstituted arylalkyl 
and substituted or unsubstituted heterocyclyl; and 
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[0128] R7 is selected from the group consisting of substi 
tuted or unsubstituted alkyl, substituted or unsubstituted 
cycloalkyl, substituted or unsubstituted alkenyl, substituted 
or unsubstituted aryl, substituted or unsubstituted arylalkyl, 
substituted or unsubstituted heterocyclyl, 4O-alkyl, i0 
aryl, 4O-arylalkyl, Oi(C:O)-alkyl, Oi(C:O)-aryl and 
Oi(C:O)-arylalkyl. 
[0129] This embodiment alloWs exchanging group Y to 
then obtain different derivatives. The nature of said acid 
medium is not of special importance and any acid system is 
suitable. Non-limiting examples of substances Which can 
give rise to an acid medium are p-toluenesulfonic acid 
(p-TsOH) or the like (for example, camphorsulfonic acid), 
inorganic acids such as hydrochloric acid or sulfuric acid, or 
acid materials such as some Zeolites. Said acids can be sup 
ported on polymer supports. 
[0130] An additional aspect of the present invention is a 
method for obtaining a compound of formula (VI), stereoi 
somers, salts or solvates thereof, Which comprises reacting a 
compound of formula (V) in an acid medium in the presence 
of a reagent Which is selected from the group consisting of 
HOR6, HSR6, Se-aryl, aryl-SeiSe-aryl, HN(R6)2, N(R6)3 
and iNHR7, Wherein R6 and R7 are as have been de?ned 
above. 
[0131] This reaction can also produce compounds of for 
mula (IX), stereoisomers, salts or solvates thereof, a method 
Which also forms an aspect of the invention. See Example 11 
beloW. 
[0132] Another aspect of the present invention is a method 
for obtaining a compound of formula (VII), stereoisomers, 
salts or solvates thereof, Which comprises reacting a com 
pound of formula (V) With a base. Said reaction involves the 
removal of groupY, and it Will therefore be more effective the 
better the leaving group Y is. In a particular embodiment, the 
reaction is performed on a compound of formula (V) Wherein 
Y is an ammonium group, i.e., a group of formula -+N(R6)3. 
[0133] An additional aspect of the present invention is a 
method for obtaining a compound of formula (VIII), stereoi 
somers, salts or solvates thereof, Which comprises reacting a 
compound of formula (IV) in an acid medium in the presence 
of a reagent Which is selected from the group consisting of 
HOR6, HSR6, Se-aryl, aryl-SeiSe-aryl, HN(R6)2, N(R6)3 
and iNHR7, Wherein R6 and R7 are as have been de?ned 
above. 
[0134] In a particular embodiment, the methods described 
also comprise the simultaneous deprotection of R9 and R10. 
[0135] In a particular embodiment, the methods described 
comprise introducing a iSe-aryl group, preferably by means 
of using phenylselenium bromide in position 9, and option 
ally its subsequent reaction With a group of formula 0R8, 
Wherein R8 is selected from the group consisting of i(C:O) 
R6 and iNHR6, Wherein R6 is as has been de?ned above. 
[0136] An additional aspect of the invention is made up of 
a method for synthesiZing a compound of formula (XII) 
Which comprises reacting a compound of formula (XI) in the 
presence of a base. According to a particular embodiment and 
similarly With the synthesis of the compounds of formula 
(IV), the base can be selected from the group consisting of 
phosphaZenes, DBU, DABCO, cyclic aliphatic amines and 
trialkylamines, preferably DBU. 
[0137] An additional aspect of the invention is made up of 
a method for synthesizing a compound of formula (XIII), 
Which comprises deprotecting the hydroxyls of positions 8 
and 10, according to the TTX numbering, removing the Pr 
group of a compound of formula (XII). For the cases Wherein 
Pr is a silicon-based protective group, for example iSi 
(Rl lR12)4OiSi(Rl lR12)i, the deprotection canbe carried 
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out With a ?uoride source or another reagent as described in 
textbooks (e.g. Greene and Nuts “Protective Groups in 
Organic Synthesis”, John Wiley & Sons, Inc., NeW Jersey, 
2007). An example of this reaction comprises Example 27 
beloW. 
[0138] An additional aspect of the invention comprises a 
method for synthesizing a compound of formula (XIV), 
Which comprises reacting a compound of formula (XII), 
Wherein X1 is iSe-aryl or iSRw, in the presence of a 
peroxide, preferably in the presence of peroxide hydroxide. 
Corresponding oxidiZed selenium (iSe(:O)-aryl) or sulfur 
(iS (:O)iRl 6) derivative is formed under these conditions 
giving rise to transposition in Which the double bond betWeen 
positions 4a and 5 (according to the TTX numbering) takes 
part and Which after hydrolysis provides the compound of 
formula @(IV). The conditions for performing this type of 
transformations are knoWn in the state of the art (see for 
example ScianoWski, J. Tetrahedron 2009, 65, 10162-10174; 
Toyofuku, M. Org. Let. 2008, 10, 3957-3960; Oshida, M. 
Chem. Pharm. Bull. 2008, 56, 404-406, for the case of sele 
nium, or Braveman, S. Rearragements Involving Sulfoxides 
The Chemistry ofSulphones and Sulphoxides, Chapter 14; 
Ed. John Wiley & Sons, 1988; p. 717-757, for the case of 
sulfur. 
[0139] Therefore, another aspect of the invention is a 
method for synthesizing TTX Which comprises transforming 
a compound of formula (XII) in a compound of formula 
(XIII) or of formula @(IV), according to the conditions 
described above. In a preferred embodiment, said compound 
of formula (XII) is obtained from a compound of formula @(I) 
according to the conditions described above. In another par 
ticular embodiment, said compound of formula @(I) is 
obtained from the compound of formula Qi) according to the 
conditions described above. 
Other Reactions 
[0140] The compounds of the invention can comprise dif 
ferent hydroxyl groups, the con?guration of Which can be 
inverted by means of a Mitsonobu reaction. For example see 
(Mitsunobu, 0.; Synthesis, 1, 1981) 
[0141] The compounds of formula (II), (III), (VI), (VIII), 
(IX), (Xa), @(I), (XII), (XIII) or (XIV) can give different 
combinations for the groups R1 and R2, all of them can be 
obtained by means of the reaction sequence described in 
PCT/EP2005/005146 and PCT/EP2005/005149, the content 
of Which is incorporated by reference. For example, see 
scheme 3. 
Scheme 3 
l . Dihydroxylation CH2 
Wittig 2. Protection 
Pr— O 
\ 
OI,“ 
/ 
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-continued 
I 
R1 and R2 
together form 
a I O group 
epoxidation 1' Ring Owning 
2. Protection 
[0142] The presence of vicinal hydroxyl groups alloWs the 
simultaneous protection of tWo or more hydroxyls. This can 
be achieved by means of using acetals, such as acetals of 
isopropylidene, cyclohexylene, cyclopentenyl, arylmethyl 
ene, diphenylmethylene, 1,2-diacetals such as dispiroketals, 
cyclohexane-1,2-diacetals, butane-2,3-diacetals, silylenes, 
1,1,3,3-tetraisopropyldisiloxanylidenes or N,O-acetals. 
Additional examples of diol protecting groups canbe found in 
reference books such as Greene and Wuts’ “Protective Groups 
in Organic Synthesis”, John Wiley & Sons, Inc., NeW York, 
1999. Borolanes can also be formed on tWo vicinal hydroxyl 
groups, for example by using phenyl boronic acid. 
[0143] Once the compounds of formula (VI), (VIII) or (IX) 
Wherein X is iCN are obtained, it is easy to obtain the 
corresponding aldehyde by reduction With DIBAL, for 
example (see example 13). 
[0144] Similarly, 4CN (position 4 according to the TTX 
numbering) in the compounds of formula (XII) or (XIII) can 
be converted into different functional groups such as 
%OORI6, iCON(Rl6)2, CHO, %H2OH, CH2N(RI6)2, 
iSe-Aryl, iSe(:O)-aryl, said aryl being able to be option 
ally substituted, iSiRm, iS(:O)R16, 4CH(ORl6)2, 
4CH(NHR16)CN and 4CH(OR16)CN. The conditions for 
said conversions are knoWn by the person skilled in the art. 
For example, aldehyde (iCH(:O)) can be obtained by 
reducing the nitrile group With DIBAL, as mentioned in the 
paragraph above. Alternatively, the 4CH2OH group can be 
obtained by aldehyde reduction in the presence of a reducing 
agent, either from the aldehyde or directly from the nitrile. In 
addition, the (4COOH) acid can be obtained by oxidiZing 
the nitrile, aldehyde or iCHzOH group, Which can in turn be 
converted into different acid derivatives such as esters 
(iCOORm), amides (4CONR16). The corresponding 
4CH2OH groups can also be converted into amines or thiols, 
or the aldehydes to be protected. The conditions for carrying 
out all these reductions are knoWn by the person skilled in the 
art and are described in reference books such as chapter 19 of 
“Advanced Organic Chemistry: reactions, mechanisms and 
structures”, March, J ., 5th edition, Wiley-interscience, for 
example. 
[0145] A iSe-aryl or iSR, group from the corresponding 
aryl can also be obtained by folloWing the knoWn methods. 
For example, reacting the corresponding hydroxyl With a 
compound of formula L-Se-aryl in the presence of a base. The 
group L is a leaving group, for example, nitrile or isoindole 
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1,3-dione. The bases can be amines or trialkylphosphorus, for 
example, n-Bu3P. More conditions Which can give rise to this 
conversion can be found for example in SWamy, K. C. K.; 
Kumar, N. N. B.; Balaraman, E.; Kumar, K.V. P. P, Chem. Rev, 
2009, 109, 2551-2651; Brian, A.; Sivaramakrishhnan, A.; 
Naka, T.; Koide, K.J.Am. Chem. Soc. 2006, 128, 2792-2793; 
Brian, A.; Sivaramakrishhnan, A.; Naka, T.; Koide, K. .1. Am. 
Chem. Soc. 2007, 129, 2648-2659; Bourland, T. C.; Carter, R. 
G.;Yokochi, A. F. T. Org. Biomol. Chem. 2004, 2, 1315-1329. 
The iSR16 group can also be introduced according to the 
conditions Which are described in UmeZaWa, T.; Hayashi, T.; 
Sakai, H.; Teramoto, H.; YoshikaWa, T.; lZumida, M.; Tama 
tani,Y.; Hirose, T.; Ohfune,Y.; Shinada, T. Org. Le”. 2006, 8, 
4971-4974; orinTsay, S.-C.; Lin, L. C.; Furth, P.A.; Shum, C. 
C.; King, D. B. Synthesis 1993, 329-334; or in Karikubo, T.; 
OgasaWara, K. J. Chem. Soc. Chem. Commun, 1995, 1951 
1 952. 
[0146] The invention Will be illustrated in more detail by 
means of the examples Which must not be interpreted as 
limiting to the scope of the claims. 
EXAMPLES 
[0147] Abbreviations and acronyms (obtained from Guide 
for Authors; Abbreviations and Acronyms .1. Org. Chem. 
2008, 78, 10A) 
Ac: acetyl 
Bn: benzyl 
Bu: butyl 
cat: catalytic l3C-NMR carbon nuclear 
magnetic resonance 
d: doublet 
DBU: 1,8-diaZabicyclo [5.4.0]undec-7-ene 
dd: doublet of doublets 
ddd: doublet of doublet ofdoublets 
DMF: N,N-dimethylformamide 
DMSO: dimethylsulfoxide 
dt: doublet of triplets 
Et: ethyl 
g: gram 
HZ: hertz 
IR: infrared spectroscopy 
1: coupling constant 
LRMS: loW resolution mass spectroscopy 
m: multiplet 
M: molarity 
mM: millimolar 
M": molecular peak 
Me: methyl 
mg: milligram 
ml: milliliter 
mmol: millimole 
m/Z: mass/charge ratio 
Rf: melting point 
ppm: parts per million 
Ph: phenyl 
Pyr: pyridine 
Yld.: yield 
s: singlet 
sat.: saturated aqueous solution 
t: triplet 
r.t.: room temperature 
TBAF: tetrabutylammonium ?uoride 
TBDMS tert-butyldimethylsilyl 
TfO: tri?uoromethanesulfonate 
THF: tetrahydro?lran 
TMS: trimethylsilyl 
Ts: p-toluenesulfonyl (tosyl) 
p-TsOH: p-toluenesulfonic acid 
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Naming and Numbering 
[0148] The cyclohexane type structures Will be named in 
the examples shoWn beloW as 2,3-dihydroxy-1-aminocyclo 
hexane derivatives and they Will be numbered according to 
the numbering indicated beloW, regardless of the substituent 
moiety Which the molecule has in any position. 
OH 
OH 
1 NH2 
4 5 
6 
2,3-dihydroxy- l 
aminocyclohexane 
‘Si/O L / Si 
O | \ 
O 
HO §\O 
Br CN \ 
Ph 
rac-(1R,2S ,3 S,4S,5 S,6R) 
5-bromo-2,3 ,4-trihydroxy 
2,3 -O-(l , l ,3,3 -tetraisopropyldisiloxane-l ,3 -diyl) 
l- (2-oxoethyl)- l- (benzyloxyamino)cyclohexane- 6-carbonitrile 
[0149] The non-spiranic bicyclic structures synthesiZed 
Will be named and numbered as indicated beloW, Which does 
not coincide With the rules established by the IUPAC 
9-oxabicyclo [3.3 . l ]non-5-ene 9-oxabicyclo [4.3 .0]non-5-ene 
Ph 
rac- (28,38 ,8R)-l -(benZyloxiamino)-2,3,8-trihydroxy-2,3-O 
(1,1,3 ,3-tetraisopropyldisiloxane-1,3 
diyl)-9-oxabicyclo [3.2.2]non-5-ene- 6-carbonitrile 
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[0150] Unless otherwise indicated, the chiral products syn 
thesiZed are racemic (rac) and Will be graphically depicted by 
means of the ?gure of one of their enantiomers. 
Materials and Methods 
[0151] All the reactions Were performed under argon atmo 
sphere, except those indicated in each case. The reagents and 
solvents used come from the commercial manufacturers Ald 
rich, Fluka, Merck, Sigma, Acros, Lancaster, SDS or Schar 
lau, and Were puri?ed by common methods (see Armarego, 
W. L.; Perrin, D. D. Puri?cation of Laboratory Chemicals; 
ButterWorth-Heinemann: Oxford, 1996.) When necessary. 
[0152] The solvents used Were distilled and dried under 
argon atmosphere as indicated beloW: CH2Cl2, toluene, ben 
Zene, DMSO and DMF on CaH2 (subsequently dry benZene 
and DMF marketed by Aldrich and Fluka, respectively, Were 
used); THF (pre-drying With KOH) and Et2O on Na/ben 
Zophenone; CH3CN, EtOH and MeOH on molecular sieve of 
4 A in pore diameter (previously activated at 150° C.). The 
CCl4 marketed by Merck Was used Without distilling. The 
dioxane Was degasi?ed by passing an argon stream before 
being used. 
[0153] The Et3N, i-PrZEtN, i-PrZNH and pyridine Were dis 
tilled under argon atmosphere on CaH2. n-BuLi marketed by 
Aldrich Was used as a 1.6 M solution in hexanes. 57-80% by 
Weight m-CPBA marketed by Aldrich Was used considering 
that its purity Was 57%. NaH (60% in mineral oil) Was Washed 
tWice With hexane under argon atmosphere immediately 
before being used. The Celite used Was Celite-545 marketed 
by SDS. 
[0154] DBU-polimer bound marketed by Aldrich With ref 
erence 595128 Was used. 
[0155] The reaction products Were puri?ed by loW-pressure 
column chromatography (?ash chromatography), using 60 
Merck silica gel (With a 230-400 mesh particle siZe) as sta 
tionary phase and previously distilled solvents as mobile 
phase. The eluent used is indicated in each case and the ratios 
of the mixture of solvents used are alWays volume/volume. 
[0156] The reactions Were monitored by thin layer chroma 
tography (TLC), using 60 F254 silica gel chromatography 
plates marketed by Merck. The plates Were developed using 
iodine vapors, 2% solution of 2,4-dinitrophenylhydraZine in 
EtOH (With 0.04% by volume of 97% H2SO4), 10% solution 
of phosphomolybdic acid in EtOH and UV light vieWer (254 
and 366 nm). 
[0157] The (completely decoupled) 1H and 13C nuclear 
magnetic resonance spectra Were performed at room tem 
perature in the solvent indicated in each case (CDCl3, 
CD3OD and DMSO-d6) using the folloWing apparatuses: 
Varian Gemini-200 (200 MHZ), Varian lNOVA-300 (300 
MHZ), Bruker Avance-300 (300 MHZ) and Varian INOVA 
400 (400 MHZ). The chemical shift values are expressed in 
parts per million (6, ppm), using as the internal reference the 
residue signal of the solvent: CDCl3, 7.26 ppm (lH-NMR) 
and 77.0 ppm (l3C-NMR); CD3OD, 3.31 ppm (lH-NMR) and 
49.0 ppm (l3C-NMR). 
[0158] The 1H-NMR spectra are described indicating the 
number of protons and the apparent multiplicity of each sig 
nal. The coupling constants (J) are those apparent and are 
expressed in HZ, The folloWing abbreviations have beenused: 
s (singlet), d (doublet), t (triplet), c (quadruplet), q (quintu 
plet) and m (multiplet). 
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[0159] The assignment of NNE signals are provided in the 
double resonance and tWo-dimensional experiment tech 
niques: DEPT (Distorsionless Enhancement by PolariZation 
Transfer), HMEC (Heteronuclear Multiple-Bond Connec 
tivities), HSQC (Heteronuclear Single Quantum Correlation) 
and nOesy (nuclear Overhauser effect spectroscopy). 
[0160] The melting points (P.f.) Were measured in a 
Reichert brand Ko?er microscope. 
[0161] The infrared spectra (IR) Were recorded in the Per 
kin-Elmer spectrophotometer models 681 and FT-IR Spec 
trum One, and the frequencies (v) of the absorption maxima 
are expressed in cm_l. The samples Were analyZed as ?lms 
betWeen NaCl crystals or in KBr discs. 
[0162] The loW resolution mass spectra (LRMS) Were 
recorded: (1) by direct injection of the sample in a HeWlett 
Packard 5973 MSD spectrophotometer using electron impact 
(El) ioniZation technique With 70 eV ioniZation energy; or (2) 
in a HeWlett Packard LCMS1100 MSD spectrophotometer 
(an HPLC-coupled quadrupole analyZer) using electrospray 
chemical ioniZation technique (APl-IS) in positive or nega 
tive modes, applying a capillary voltage of 4000 V, a drying 
temperature of 3300 C. and using a [1:1] H2O/MeOH mixture 
With 1% AcOH as a carrier. The data obtained are expressed 
in mass units (m/Z) and the values in parenthesis correspond 
to the relative intensities With respect to the base peak 
(100%). The molecular peak is speci?ed as M". 
Example 1 
Preparation of rac-(4R,5 S,6S)-1-benZyloxy-8 
bromo-5,6-dihydroxy-5,6-O-(1, 1,3,3 -tetraisopropyl 
disiloxane-1,3 -diyl)-1 -aZaspiro [3 . 5]non-8-en-2,7 
dione 
[0163] 
OY Si/ \sf/k 
\ O 
O o 1) BIZ 
2) Et3N 
N O 
/ 
O 
\—Ph 
(>6 Si/ \sf/k 
\ O 
O\O 
Br 
N O 
/ 
O 
\—Ph 
[0164] A solution ofBr2 (64.9 mg, 0.40 mmol, 1.08 eq.) in 
CH2Cl2 (1 ml) Was added in a solution of rac-(4R,5S,6S)-1 
benZyloxy-5,6-dihydroxy-5,6-O-(1,1,3,3-tetraisopropyldisi 
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loxane-1,3-diyl)-1-aZaspiro[3.5]non-8-ene-2,7-dione (200 
mg, 0.376 mmol, 1.0 eq) in CH2Cl2 (1 ml) at 0° C. The 
resulting mixture Was stirred at 0° C. for 10 minutes. After 
that time, Et3N (57.08 mg, 0.564 mmol, 1.5 eq) Was added 
dropWise. The mixture Was stirred at room temperature for 10 
minutes. The solvent Was then removed at reduced pressure. 
The residue Was titrated With Et2O, it Was ?ltered through 
Celite and the solvent Was removed at reduced pressure. The 
product Was puri?ed by means of column chromatography 
(hexane/AcOEt; 6:1), rac-(4R,5S,6S)-1-benZyloxy-8 
bromo-5,6-dihydroxy-5,6-O-(1,1,3,3 -tetraisopropyldisilox 
ane-1,3-diyl)-1-aZaspiro[3.5]non-8-ene-2,7-dione (210 mg; 
yld.: 92%) being obtained as a broWn oil. 
[0165] lH-NMR (6): 7.37 (5H, m, AriH); 6.40 (1H, s); 
4.96 (1H, m); 4.84 (1H, d, 1:30 HZ); 4.41 (1H, d, 1:30 HZ); 
3.21 (1H, d, J:14.2 HZ); 2.61 (1H, d, J:14.2 HZ); 1.04 (28H, 
m). 
Example 2 
Preparation of rac-(4R,5 S,6S,8R,9S)-1-benZyloxy-8 
bromo-9-cyano-5,6-dihydroxy-5,6-O-(1,1,3,3-tetrai 
sopropyldisiloxane-1,3 -diyl)- 1 -aZaspiro [3 ,5]nonane 
2,7-dione 
[0167] 
OY Si/ \sil/k 
\ O 
o o 1)Et2AlCN 
—> 
2) NBS, THF 
N O 
/ 
O 
\—Ph 
: 01/ Si/ SEA 
\ O 
O\O 
Br 
CN 
N O 
/ 
O 
\—Ph 
[0168] EtZAlCN (501.48 mg, 4.512 mmol, 1.2 eq.) Was 
added in a solution of rac-(4R,5S,6S)- 1 -benZyloxy-5,6-dihy 
droxy-5,6-O-(1,1,3,3-tetraisopropyldisiloxane-1,3-diyl)-1 
aZaspiro[3.5]non-B-ene-2,7-dione (2 g, 3.76 mmol, 1.0 eq) in 
THF (30 ml) at 0° C. The mixture Was heated to 80° C. for 3 
hours. After that time, the mixture Was cooled to 0° C. and 
NBS (1.003 g, 5.64 mmol, 1.5 eq.) Was added in portions. The 
resulting solution Was stirred a r.t. for 15 minutes. After that 
time, the solvent Was removed at reduced pressure. The resi 
due Was titrated With Et2O, it Was ?ltered through Celite and 
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the solvent Was removed at reduced pressure. The product, 
rac-(4R,5S,6S,8R,9S)-1-benZyloxy-8-bromo-9-cyano-5,6 
dihydroxy-5,6-O-(1,1,3,3-tetraisopropyldisiloxane-1,3 
diyl)-1-aZaspiro[3.5]nonane-2,7-dione, Was used in the fol 
loWing reaction Without purifying (the yield has been 
considered quantitative). 
[0169] lH-NMR (6): 7.46 (5H, m, AriH); 5.30 (1H, d, 
J:11.1 HZ); 5.19 (1H, d, J:11.1 HZ); 5.07 (1H, dd, J:1.1, 2.3 
HZ); 4.34 (1H, d, 1:23 HZ); 4.22 (1H, dd, J:1.1, 12.6 HZ); 
3.88 (1H, d, 1:126 HZ); 3.06 (1H, d, 1:145 HZ); 2.85 (1H, d, 
1:145 HZ); 1.25-0.82 (28H, m). 
Example 3 
Preparation of rac-(1R,2S,3S,4R,5 S,6R)-5 -bromo-1 
(2 -oxoethyl) -2,3 ,4-trihydroxy-2,3-O-( 1 , 1 ,3 ,3 -tetrai 
sopropyldisiloxane-1,3-diyl)-1-(benZyloxyamino) 
cyclohexane-6-carbonitrile 
[0171] 
< J Si/ 11/4 
\ O 
O\o DIBAL 
THF 
Br 
CN 
N O 
/ 
O 
\—Ph 
(:6 Si/ 11/4 
HO\ O 
O 
O 
Br / 
CN 
NH 
/ 
O 
\—Ph 
[0172] DIBAL (2.169 g, 15.04 mmol, 4 eq.) Was added in a 
solution of rac-(4R,5S,6S,8R,9S)-1-benZyloxy-8-bromo-9 
cyano-5,6-dihydroxy-5,6-O-(1, 1,3,3 -tetraisopropyldisilox 
ane-1,3-diyl)-1-aZaspiro[3.5]nonane-2,7-dione (2.39 g, 3.76 
mmol, 1 eq.) in THF (50 ml) at 0° C. The mixture Was stirred 
at 0° C. for 3 minutes. After that time, AcOEt (30 ml) Was 
added. The resulting mixture Was stirred at O'C for 10 min 
utes. H20 (30 ml) Was then added. The phases Were separated, 
and the aqueous phase Was extracted With AcOEt (4><20 ml). 
The organic phase Was dried With anhydrous Na2SO4, it Was 
?ltered and the solvent Was removed at reduced pressure. The 
product Was puri?ed by means of column chromatography 
(hexane/AcOEt, 9: 1), rac-(1R,2S,3S,4R,5S,6R)-5-bromo-1 
(2-oxoethyl) -2,3 ,4-trihydroxy-2,3 -O-(1,1,3,3 -tetraisopropy 
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ldisiloxane-1,3 -diyl)-1-(benZyloxyamino)cyclohexane-6 
carbonitrile (866 mg, yld.: 32%) being obtained as a White 
solid. 
[0173] Pf.: 103-104° C. 
[0174] lH-NMR (6): 9.74 (1H, s); 7.36 (5H, m, AriH); 
6.07 (1H, s); 4.77 (1H, d, 1:1 1.7 HZ); 4.68 (1H, d, 1:1 1.7 HZ); 
4.49 (1H, m); 4.35 (1H, dd, 1:25, 11.8 HZ); 4.16 (1H, m); 
4.15 (1H, m); 3.54 (1H, d, 1:118 HZ); 3.50 (1H, d, 1:185 
HZ); 2.91 (1H, d, 1:46 HZ); 2.87 (1H, d, 1:185 HZ); 1.047 
(28H, m). 
[0175] l3C-NMR (6): 199.3, 136.2, 128.8, 128.5, 128.3, 
118.3, 76.7, 73.1, 72.5, 71.3, 661,476, 43.7, 36.3, 17.6, 17.4, 
17.4,17.2,17.1,17.1,17.0,17.0,13.9,13.4,13.0,12.5. 
[0176] LRMS(APl-lS+)ZII1/Z 641 (M+H)+, 1304 (2M+Na+ 
H)". 
[0177] IR (KBr): v 3523, 2946, 2867, 2246, 1720, 1464, 
1388, 1248, 1162, 1014, 885, 754, 698 cm_l. 
Example 4 
Preparation of rac-(4R,5S,6S,9S)-1-benZyloxy-9 
cyano-5,6,7-trihydroxy-5,6-O-(1,1,3,3-tetraisopropy 
ldisiloxane-1,3 -diyl)-1-aZaspiro[3.5]nonan-2-one 
[0178] 
#34. How CNN Ph \OJ 
[0179] NaBH4 (15.65 mg, 0.41 mmol, 1.1 eq.) Was added in 
a solution of rac-(4R,5S,6S,8R,9S)-1 -benZyloxy-8-bromo-9 
cyano-5,6-dihydroxy-5,6-O-(1,1,3,3 -tetraisopropyldisilox 
ane-1,3-diyl)-1-aZaspiro[3.5]nonane-2,7-dione (239 mg, 
0.376 mmol, 1.0 eq) in EtOH (10 ml) at 0° C. The mixture Was 
stirred at 0° C. for 30 minutes. After that time, H20 (20 ml) 
Was added at 0° C. The phases Were separated, and the aque 
ous phase Was extracted With AcOEt (3><10 ml). The organic 
phase Was dried With anhydrous Na2SO4, it Was ?ltered and 
the solvent Was removed at reduced pressure. The product 
Was puri?ed by means of column chromatography (hexane/ 
AcOEt, 9:1), rac-(4R,5S,6S,9S)-1-benZyloxy-9-cyano-5,6, 
7-trihydroxy-5,6-O-(1, 1,3,3 -tetraisopropyldisiloxane-1,3 - 
diyl)-1-aZaspiro[3.5]nonan-2-one (44 mg, yld.: 21%) being 
obtained as a White solid. 
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[0180] lH-NMR (0); 7.41 (5H, m, A1411); 5.04 (1H, d, 
1:120 HZ); 4.87 (1H, d, 1:120 HZ); 4.46 (1H, m); 4.09 (1H, 
d, 1:31 HZ); 3.90 (1H, d, 1:31 HZ); 3.32 (1H, m); 3.10 (1H, 
d, 1:141 HZ); 2.66 (1H, d, 1:141 HZ); 1.69 (2H, m); 1.05 
(28H, m). 
[0181] LRMS (API-IS”): III/Z 561 (M+H)+, 583 (M+Na)+, 
1144 (2M+Na+H)+. 
Example 5 
Preparation of rac-(1R,2S,3S,4R,5 S,6R)-5 -bromo-1 
(2-hydroxyethyl)-2,3 ,4-trihydroxy-2,3 -O-(1,1,3,3 
tetraisopropyldisiloxane-1,3 -diyl)-1-(henZy 
loxyamino)cyclohexane- 6-carbonitrile 
[0182] 
01/ Si/ SC/Q 
Ho\ 0 
O 
NaBH4 
B /0 EtOH 
I 
CN 
NH 
/ 
0 
\—Ph 
0:6 81/ SC/Q 
Ho\ 0 
O 
OH 
Br 
CN 
NH 
/ 
0 
\—Ph 
[0183] NaBH4 (26.0 mg, 0.687 mmol, 1.1eq.)Was added in 
a solution of rac-(1R,2S,3S,4R,5S,6R)-5-bromo-1-(2-oxoet 
hyl)-2,3,4-trihydroxy-2,3 -O-(1,1,3,3 -tetraisopropyldisilox 
ane-1,3 -diyl)-1-(benZyloxyamino)-cyclohexane-6-carboni 
trile (0.4 g, 0.625 mmol, 1 eq.) in EtOH (16 ml) at 0° C. The 
resulting mixture Was stirred at 0° C. for 5 minutes. After that 
time, an aqueous solution of 0.1 M NaHPO4 (8 ml) andAcOEt 
(10 ml) Was added. The phases Were separated, and the aque 
ous phase Was extracted With AcOEt (3><5 ml). The organic 
phase Was dried With anhydrous Na2SO4, it Was ?ltered and 
the solvent Was removed at reduced pressure. The product 
Was puri?ed by means of column chromatography (hexane/ 
AcOEt, 8:1), rac-(1R,2S,3S,4R,5S,6R)-5-bromo-1-(2-hy 
droxyethyl)-2,3 ,4-trihydroxy-2,3 -O-(1,1,3,3-tetraisopropyl 
disiloxane-1,3 -diyl)-1-(benZyloxyamino)cyclohexane-6 
carbonitrile (330 mg, yld.: 82%) being obtained as a colorless 
oil. 
[0184] lH-NMR (6): 7.36 (5H, m, AriH); 5.93 (1H, s); 
4.72 (2H, s, iOCHzPh); 4.46 (1H, d, 1:24 HZ); 4.45 (1H, 
dd, 1:27, 11.7 HZ); 4.33 (1H, m); 4.19 (1H, m); 3.89 (1H, m); 
3.50 (1H, d, 1:1 1.7 HZ); 3.15 (1H, d, 1:56 HZ); 2.34 (1H, m); 
2.26 (1H, m); 2.13 (1H, m); 1.06 (28H, m). 
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[0185] l3c-NMR (0): 135.8, 128.7, 128.6, 128.5, 118.6, 
77.0, 73.6, 73.4, 71.3, 66.3, 58.1, 49.1, 37.9, 36.3, 17.7, 17.4, 
17.4,17.3,17.2, 17.2, 17.1, 17.1,14.1,13.5, 13.2. 
[0186] LRMS (API-IS”): III/Z 643 (M+H)", 644 (M+2H)", 
645 (M+3H)", 665 (M+Na+H)", 1308 (2M+Na+H)+. 
[0187] IR (KBr): v 3468, 3027, 2945, 2890, 2867, 2247, 
1464, 1386, 1160, 1013, 885, 697 cm'l. 
Example 6 
Preparation of rac-(1R,2S,3S,4R,5S,6R)-5 -bromo-1 
(2 -tert-butyldimethylsilyloxyethyl) -2,3 ,4-trihydroxy 
2,3 —O-(l , 1,3,3-tetraisopropyldisiloxane-1,3-diyl)-1 - 
(benZyloxyamino)cyclohexane-6-carbonitrile 
[0188] 
01/ Si/ sil/k 
HO\ O 
O 
OH TBDMSCl 
Br imidazole 
CN 
NH 
/ 
O 
\— Ph 
(:6 81/ 811/4 
HO\ O 
O 
OTBDMS 
Br 
CN 
NH 
/ 
O 
\—Ph 
[0189] A solution ofTHDMSCl (303 mg, 1.697 mmol, 3.3 
eq.) in DMF (5 ml) Was added in a solution ofrac-(1R,2S,3S, 
4R,5 S,6R)-5-bromo-1-(2-hydroxyethyl)-2,3,4-trihydroxy-2, 
3-O-(1,1,3,3-tetraisopropyldisiloxane-1,3-diyl)-1-(benZy 
loxyamino)cyclohexane-6-carbonitrile (330 mg, 0.514 
mmol, 1 eq.) and imidaZole (115 mg, 1.697 mmol, 3.3 eq.) in 
DMF (12 ml) at 0° C. The resulting mixture Was stirred at 
room temperature for 16 hours. After that time, H20 (15 ml) 
and AcOEt (15 ml) Were added. The phases Were separated, 
and the aqueous phase Was extracted With AcOEt (4><7 ml). 
The organic phase Was Washed With a saturated aqueous 
solution of CuSO4><15 ml) and brine (4><7 ml), it Was dried 
With anhydrous Na2SO4, it Was ?ltered and the solvent Was 
removed at reduced pressure. The product Was puri?ed by 
means of column chromatography (hexane/AcOEt, 30:1), 
rac-(1R,2S,3S,4R,5S,6R)-5-bromo-1-(2-tert-butyldimethyl 
silyloxyethyl) -2,3 ,4-trihydroxy-2,3 -O-(1,1,3,3 -tetraisopro 
pyldisiloxane-1,3 -diyl)-1-(benZyloxyamino)cyclohexane-6 
carbonitrile (264 mg, yld.: 68%) being obtained as a colorless 
oil. 
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[0190] lH-NMR (6): 7.36 (5H, m, AriH); 6.00 (1H, s); 
4.67 (1H, d, 1:150 HZ); 4.65 (1H, d, 1:150 HZ); 4.43 (1H, 
shroud); 4.37 (2H, m); 4.15 (1H, m); 3.92 (2H, m); 3.52 (1H, d, 
J:11.9 HZ); 3.21 (1H, d, 1:56 HZ); 2.32 (1H, dt, J:7.4, 13.6 
HZ); 2.04 (1H, dt, 1:67, 7.4 HZ); 1.06 (28H, m); 0.86 (9H, s); 
0.03 (6H, s). 
[0191] l3C-NMR (6): 136.4, 128.6, 128.5, 128.3, 118.7, 
77.2, 76.7, 74.3, 73.7, 71.3, 66.1, 59.3, 49.2, 37.5, 37.4, 36.1, 
25.8,18.1,17.8,17.4,17.3,17.3,17.2,17.1,17.0,14.2,13.4, 
13.2,13.1,—5.5. 
[0192] LRMS (APl-IS”): m/Z 760 (M+2H)", 782 (M+Na+ 
H)", 1540 (2M+Na+H)+. 
Example 7 
Reaction of rac-(1R,2S,3 S,4R,5 S, 6R)-5 -bromo-1-(2 
oxoethyl)-2,3,4-trihydroxy-2,3 -O-(1,1,3,3 -tetraiso 
propyldisiloxane-1,3 -diyl)-1-(benZyloxyamino)cy 
clohexane-6-carbonitrile With DBU 
[0193] 
OY Si/ \SF/Q 
Ho\ 0 
O 
O DBU 
/ 0112012 Br 
CN 
NH 
/ 
O 
\—Ph 
HO O >* 
Br O——?i\( O\ ./O + 
S1 
HN 
CN| 
0) 
Ph 
HO O >* 
07% / O\Si/O 
NC HN 
6 
PhJ 
[0194] DBU (24 mg, 0.156 mmol, 1 eq.) Was added in a 
solution of rac-(1R,2S,3S,4R,5S,6R)-5-bromo-1-(2-oxoet 
hyl)-2,3,4-trihydroxy-2,3 -O-(1,1,3,3 -tetraisopropyldisilox 
ane-1,3 -diyl)-1-(benZyloxyamino)cyclohexane-6-carboni 
trile (100 mg, 0.156 mmol, 1 eq.) in CH2Cl2 (2 ml) at 00 C. 
The resulting mixture Was stirred at room temperature for 3 
hours. After that time, CH2Cl2 (10 ml) Was added and the 
mixture Was Washed With a saturated aqueous solution of 
CuSO4 (1><5 ml) and brine (1><5 ml), it Was dried With anhy 
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drous Na2SO4, it Was ?ltered and the solvent Was removed at 
reduced pressure. The product Was puri?ed by means of col 
umn chromatography (hexane/AcOEt, 8:1), rac-(2S,3S,5S, 
6R,8R)-1-(benZyloxyamino)-5-bromo-2,3,8-trihydroxy-2,3 
O-(1,1,3,3-tetraisopropyldisiloxane-1,3-diyl)-9-oxabicyclo 
[3.2.2]nonane-6-carbonitrile (36 mg, yld.: 36%) being 
obtained as a colorless oil, and rac-(2S,3S,8R)-1-(benZy 
loxyamino)-2,3,8-trihydroxy-2,3-O-(1,1,3,3 -tetraisopropyl 
disiloxane-1,3-diyl)-9-oxabicyclo[3.2.2]non-5-ene-6-carbo 
nitrile (34 mg, yld.: 39%) as a White solid. 
[0195] rac-(2S,3S,5S,6R,8R)-1-(benZyloxyamino)-5 
bromo -2,3 ,8-trihydroxy-2,3 -O-(1,1,3,3 -tetraisopropyldisi 
loxane-1,3 -diyl)-9-oxabicyclo[3 .2 .2]nonane-6-carbonitrile. 
Ph 
[0196] lH-NMR (6): 7.35 (5H, m, AriH); 5.87 (1H, 
shroud); 5.47 (1H, m); 4.76 (1H, d, 1:173 HZ); 4.72 (1H, d, 
J:17.3 HZ); 4.61 (1H, dd, 1:25, 11.7 HZ); 4.39 (2H, m); 4.04 
(1H, m); 3.60 (1H, d, J:11.7 HZ); 2.66 (1H, m); 2.31 (1H, dd, 
J:5.7, 14.1 HZ); 2.03 (1H, m); 1.03 (28H, m). 
[0197] LRMS (APl-IS”): m/Z 623 (M—H2O)+, 624 
(M—H2O+H)+, 625 (M—H2O+2H)+, 665 (M+Na+H)+. 
[0198] (2S,3S,8R)-1-(benZyloxyamino)-2,3,8-trihydroxy 
2,3-O-(1,1,3,3-tetraisopropyldisiloxane-1,3-diyl)-9-oxabi 
cyclo[3.2.2]non-5-ene-6-carbonitrile. 
WW / O\Si/O 
NC HN 
PhJ 
[0199] Pf.:148-149°C. 
[0200] lH-NMR (0): 7.33 (5H, m, A1411), 6.53 (1H, dd, 
1:18, 3.6 HZ); 5.87 (1H, s); 5.48 (1H, dd, 1:53, 9.3 HZ); 4.79 
(1H, d, 1:117 HZ, ADCHZPh); 4.73 (1H, d, 1:117 HZ, 
iOCHZPh); 4.65 (2H, m); 4.43 (1H, dd, 1:21, 4.9 HZ); 3.68 
(1H, d, 1:80 HZ); 2.47 (1H, dd, 1:53, 13.3 HZ); 1.81 (1H, d, 
1:133 HZ); 1.06 (28H, m). 
[0201] l3c-NMR (0): 148.6, 136.5, 128.6, 128.4, 128.3, 
116.2, 113.5, 99.3, 79.1, 77.4, 73.4, 72.2, 67.4, 42.4, 17.4, 
17.4,17.2,17.2, 17.0, 17.0, 17.0,14.0,13.6, 12.9, 12.4. 
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[0203] IR (KBr): v 3448, 3275, 2946, 2867, 2233, 1639, 
1462,1363,1246,1189,1141,1070,1011,884,803,695,619 
-1 
cm . 
Example 8 
[0204] Optimized methods for the preparation of rac-(2S, 
3S,8R)-1-(benZyloxyamino)-2,3,8-trihydroxy-2,3-O-(1,1,3, 
3 -tetraisopropyldisiloxane-1,3 -diyl)-9-oxabicyclo [3 .2.2] 
non-5-ene-6-carbonitrile. 
[0205] iMethod 1. 
0:6 81/ sll/k 
Ho\ 0 
O 
DBU 
/ cH2c12 Br 
CN 
NH 
/ 
0 
\—Ph 
HO O >* 
71% 
PhJ 
[0206] DBU (67 mg, 0.434 mmol, 1.3 eq.) Was added in a 
solution of rac-(1R,2S,3S,4R,5S,6R)-5-bromo-1-(2-oxoet 
hyl)-2,3,4-trihydroxy-2,3 -O-(1,1,3,3 -tetraisopropyldisilox 
ane-1,3 -diyl)-1-(benZyloxyamino)cyclohexane-6-carboni 
trile (214 mg, 0.333 mmol, 1 eq.) in CH2Cl2 (4 ml) at 00 C. 
The resulting mixture Was stirred at room temperature for 16 
hours. After that time, CH2Cl2 (10 ml) Was added and the 
mixture Was Washed With a saturated aqueous solution of 
citric acid (2><5 ml), it Was dried With anhydrous Na2SO4, it 
Was ?ltered and the solvent Was removed at reduced pressure. 
The product Was puri?ed by means of column chromatogra 
phy (hexane/AcOEt, 8:1), rac-(2S,3S,8R)-1-(benZy 
loxyamino)-2,3,8-trihydroxy-2,3-O-(1, 1,3,3 -tetraisopropyl 
disiloxane-1,3-diyl)-9-oxabicyclo[3.2.2]non-5-ene-6 
carbonitrile (108 mg, yld.: 58%) being obtained as a White 
solid. 
[0207] iMethod 2. 
CY 81/ Silk 
HO\ O 
O 
DBU-polymer bound 
Br /0 0112012 
CN 
NH 
/ 
0 
\—Ph 
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HO 
NC 
PhJ 
[0208] CH2Cl2 (11 ml) Was added in a mixture of rac-(1R, 
2S,3S,4R,5S,6R)-5-bromo-1-(2-oxoethyl)-2,3,4-trihydroxy 
2,3-O-(1,1,3,3-tetraisopropyldisiloxane-1,3-diyl)-1-(benZy 
loxyamino)cyclohexane-6-carbonitrile (553 mg, 0.862 
mmol, 1 eq.) and DBU-polymer bound (1.5 g, 1.724 mmol, 
2.0 eq.) at 0° C. The resulting mixture Was stirred at room 
temperature for 11 hours. After that time, the mixture Was 
?ltered in a biichner With AcOEt and the solvent Was removed 
at reduced pressure. The product Was puri?ed by means of 
column chromatography (hexane/AcOEt, 8:1), rac-(2S,3S, 
8R)-1-(benZyloxyamino)-2,3,8-trihydroxy-2,3-O-(1,1,3,3 
tetraisopropyldisiloxane-1,3 -diyl)-9-oxabicyclo [3 .2.2]non 
5-ene-6-carbonitrile (256 mg, yld.: 53%) being obtained as a 
White solid. 
Example 9 
Preparation of rac-(2S,3S,5S,6R,8R)-1-(benZy 
loxyamino)-5 -bromo -2,3 ,8-trihydroxy-9-oxabicyclo 
[3 .2.2]nonane-6-carbonitrile 
[0209] 
HO O >* 
Br O_Si\( 2HF-Et3N | —> 
o\S/o cH2c12 1 
HN 
CN| 
0) 
Ph 
HO 0 
Br OH 
OH 
HN 
CN I 
O 
Ph 
[0210] 3HF.Et3N (310 mg, 1.928 mmol, 36 eq.) Was added 
in a solution of rac-(2S,3S,5S,6R,8R)-1-(benZyloxyamino) 
5-bromo-2,3,8-trihydroxy-2,3-O-(1,1,3,3-tetraisopropyld 
isiloxane- 1 ,3-diyl)-9-oxabicyclo [3 .2.2]nonane-6-carboni 
trile (31 mg, 0.054 mmol, 1 eq.) in MeOH (3 ml). The mixture 
Was stirred at room temperature for 24 hours. After that time, 
an aqueous solution of NaZHPO4 (0.1M, 3 ml) and AcOEt (6 
ml) Was added. The phases Were separated, and the aqueous 
19 
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phase Was extracted With AcOEt (3><5 ml). The organic phase 
Was dried With anhydrous Na2SO4, it Was ?ltered and the 
solvent Was removed at reduced pressure. The product Was 
puri?ed by means of column chromatography (hexane/ 
AcOEt, 1:8), rac-(2S,3S,5S,6R,8R)-1-(benZyloxyamino)-5 
bromo-2,3,8-trihydroxy-9-oxabicyclo[3.2.2]nonane-6-car 
bonitrile (8 mg, yld.; 37%) being obtained. 
[0211] lH-NMR (6): 7.34 (5H, m); 5.94 (1H, shroud); 5.56 
(1H, m); 4.71 (2H, m); 4.63 (1H, m); 4.49 (1H, m); 4.21 (2H, 
m); 3.82 (1H, m); 3.53 (1H, m); 3.44 (1H, d, 1:1 1.9 HZ); 3.24 
(1H, m); 2.26 (1H, m); 2.04 (1H, m). 
[0212] LRMS (APT-IS”): m/Z 3 81 (M—H2O)+, 421 
(M+Na)+. 
Example 10 
Preparation of rac-(2S,3 S,8R)-1-(benZyloxyamino) 
2,3 ,8-trihydroxy-9-oxabicyclo [3 .2 .2]non-5 -ene-6 
carbonitrile 
[0213] 
HO O >— 
O — Si \( | 3HF-Et3N 
/ O\Si/O MeOH ' 
NC HIT 
O 
Ph J 
HO O 
OH 
/ OH 
NC HN 
[0214] 3HF.Et3N (517 mg, 3.209 mmol, 36 eq.) Was added 
in a solution of rac-(2S,3S,8R)-1-(benZyloxyamino)-2,3,8 
trihydroxy-2,3 -O-(1,1,3,3-tetraisopropyldisiloxane-1,3 
diyl)-9-oxabicyclo[3.2.2]non-5-ene-6-carbonitrile (50 mg, 
0.089 mmol, 1 eq.) in MeOH (5 ml). The mixture Was stirred 
at room temperature for 24 hours. After that time, an aqueous 
solution of NaZHPO4 (0.1M, 5 ml) and AcOEt (10 ml) Was 
added. The phases Were separated, and the aqueous phase Was 
extracted With AcOEt (3><4 ml). The organic phase Was dried 
With anhydrous Na2SO4, it Was ?ltered and the solvent Was 
removed at reduced pressure. The product Was puri?ed by 
means of column chromatography (hexane/AcOEt, 1:8), rac 
(2S,3S,8R)-1-(benZyloxyamino)-2,3,8-trihydroxy-9-oxabi 
cyclo[3.2.2]non-5-ene-6-carbonitrile (26 mg, yld.: 93%) 
being obtained. 
[0215] lH-NMR (6): 7.31 (5H, m); 6.64 (1H, shroud); 5.54 
(1H, d, 1:51 HZ); 4.71 (3H, m); 4.33 (1H, m); 4.17 (1H, m); 
2.58 (1H, shroud) 2.31 (1H, dd, 1:51, 13.8 HZ); 1.93 (1H, d, 
1:138 HZ); 
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